Mesenchymal Stem Cells and Reticulated Platelets: New Horizons in Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Cell Biology

Background:

• Multiple myeloma (MM) is a plasma cell malignancy.
• Mesenchymal stem cells (MSCs) and reticulated platelets (RPs) are increasingly recognized for their roles in MM pathogenesis.
• The bone marrow microenvironment, influenced by MSCs and RPs, is critical for MM progression.

Purpose of the Study:

• To review the role of MSCs and RPs in the pathophysiology of MM.
• To explore the potential clinical utility of MSCs and RPs as prognostic indicators in MM.
• To discuss the integration of MSC and RP evaluation into clinical practice for MM management.

Main Methods:

• This study is a narrative review.
• Literature search on the involvement of MSCs and RPs in MM.
• Analysis of existing research on MM pathophysiology and potential biomarkers.

Main Results:

• MSCs support MM cell survival, proliferation, and drug resistance via secreted factors.
• RPs promote angiogenesis, tumor growth, and metastasis in MM.
• Current clinical evaluations for MM do not typically include MSCs or RPs.

Conclusions:

• MSCs and RPs are integral to MM biology and progression.
• Evaluating MSCs and RPs may provide valuable prognostic information for MM patients.
• Incorporating MSC and RP assessment into clinical practice could enhance MM outcome prediction and management strategies.